恩瑞格疗效好吗？

In 2010, Deferasirox was approved for marketing in China and is approved for the treatment of chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients aged 2 years and above and chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above.

In 2012, Deferasirox was approved in the EU for the treatment of patients with chronic iron overload thalassemia aged 6 years and older due to frequent blood transfusions (hematocrit ≥7ml/kg/month). It was also approved for the treatment of chronic iron overload caused by blood transfusions when deferoxamine treatment is contraindicated or insufficient. In Japan, this product is approved for the treatment of iron overload caused by blood transfusion.

So, is Enrig’s treatment good?

Iron overload is a major complication in transfusion-dependent patients. Severe iron overload can cause functional damage to tissues and organs such as the heart and liver, becoming the main cause of death for patients, especially patients with β-thalassemia major. The combined iron-removing therapy of deferoxamine and deferiprone can effectively improve the condition of patients with iron overload, but the cumbersome medication method greatly affects treatment compliance. Deferasirox is a new oral iron chelator with good safety and tolerability, and is easy to take once a day.

Enrig can remove free iron and intracellular iron, prevent myocardial cells from absorbing iron, and directly remove excess iron from myocardial cells, resulting in a continuous reduction of non-transferrin in plasma. It is the first-line drug for patients with chronic iron overload caused by blood transfusion. Enrige dispersible tablets can be taken orally once a day, with good patient compliance, ensuring long-term iron removal treatment.

Its good iron-removing effectiveness, safety and patient compliance have greatly reduced the mortality of patients with diseases such as thalassemia and MDS that require long-term blood transfusion treatment, and improved their quality of life.